172 related articles for article (PubMed ID: 29255206)
1. Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.
Shen Z; Rodriguez-Garcia M; Patel MV; Bodwell J; Kashuba ADM; Wira CR
Sci Rep; 2017 Dec; 7(1):17697. PubMed ID: 29255206
[TBL] [Abstract][Full Text] [Related]
2. Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells.
Shen Z; Rodriguez-Garcia M; Patel MV; Bodwell J; Wira CR
Sci Rep; 2019 Feb; 9(1):1864. PubMed ID: 30755713
[TBL] [Abstract][Full Text] [Related]
3. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
4. Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture.
Shen Z; Fahey JV; Bodwell JE; Rodriguez-Garcia M; Kashuba AD; Wira CR
PLoS One; 2014; 9(6):e100863. PubMed ID: 24978212
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method.
Ouyang B; Zhou F; Zhen L; Peng Y; Sun J; Chen Q; Jin X; Wang G; Zhang J
J Pharm Biomed Anal; 2017 Nov; 146():147-153. PubMed ID: 28881311
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.
Rodriguez-Garcia M; Patel MV; Shen Z; Bodwell J; Rossoll RM; Wira CR
Sci Rep; 2017 Apr; 8():45725. PubMed ID: 28368028
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
Margot N; Ram R; Abram M; Haubrich R; Callebaut C
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104
[TBL] [Abstract][Full Text] [Related]
8. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
[TBL] [Abstract][Full Text] [Related]
10. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
[TBL] [Abstract][Full Text] [Related]
11. Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors.
Birkus G; Bam RA; Willkom M; Frey CR; Tsai L; Stray KM; Yant SR; Cihlar T
Antimicrob Agents Chemother; 2016 Jan; 60(1):316-22. PubMed ID: 26503655
[TBL] [Abstract][Full Text] [Related]
12. Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy.
Ma B; Barth A; McHale CM; Lai MT
Antiviral Res; 2018 Mar; 151():1-3. PubMed ID: 29337165
[TBL] [Abstract][Full Text] [Related]
13. Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis.
Nicol MR; Eneh P; Nakalega R; Kaiser T; Kabwigu S; Isingel E; Beksinska M; Sykes C; Fowler MG; Brown TT; Staley C; Kiweewa Matovu F
Clin Infect Dis; 2020 Apr; 70(8):1717-1724. PubMed ID: 31131846
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors.
Bam RA; Birkus G; Babusis D; Cihlar T; Yant SR
Antivir Ther; 2014; 19(7):669-77. PubMed ID: 24625459
[TBL] [Abstract][Full Text] [Related]
16. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
[TBL] [Abstract][Full Text] [Related]
17. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
Margot NA; Liu Y; Miller MD; Callebaut C
Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
[TBL] [Abstract][Full Text] [Related]
18. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
Dumond JB; Greene SA; Prince HMA; Chen J; Maas BM; Sykes C; Schauer AP; Blake KH; Nelson JAE; Gay CL; Kashuba ADM; Cohen MS
Antivir Ther; 2019; 24(1):45-50. PubMed ID: 30375984
[TBL] [Abstract][Full Text] [Related]
19. Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
Margot NA; Johnson A; Miller MD; Callebaut C
Antimicrob Agents Chemother; 2015 Oct; 59(10):5917-24. PubMed ID: 26149983
[TBL] [Abstract][Full Text] [Related]
20. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
